FINANCING EXPENSES, NET

9 Months Ended

Sep. 30, 2021

FINANCING EXPENSES, NET

NOTE 6 - FINANCING EXPENSES, NET

	Nine months period ended September 30,						Three months period ended September 30,
	2021			2020			2021			2020
	Unaudited			Unaudited			Unaudited			Unaudited
Modification of terms relating to straight loan transaction	$	88		$	-		$	-		$	-
Modification of terms relating to convertible bridge loans transactions		-			(3,495	)		-			(7,334	)
Exchange differences relating to loans from shareholders		-			40			-			(43	)
Issuance of ordinary shares and stock warrants upon modification of terms relating to convertible bridge loans transactions					415						415
Issuance of shares as a settlement in excess of the carrying amount of financial liabilities		-			1,234			-			734
Amortization of discounts and accrued interest on convertible bridge loans		18,080			8,393			4,432			10,896
Amortization of discounts and accrued interest on straight loans		2,290			-			1,637			-
Change in fair value of derivative warrants liability and fair value of warrants expired		(299	)		-			(5	)		-
Change in fair value of liability related to conversion feature of convertible bridge loans		(3,777	)		-			530			-
Issuance of shares as call options to acquire potential acquire		-			3,000			-			1,000
Settlement in cash of prepayment obligation related to convertible bridge loan		182						182
Interest and related royalties under receivables financing facility		546			633			495			633
Amortization of prepaid expenses related to commitment shares in connection with receivables financing facility and equity line		293			61			293			-
Exchange rate differences and other finance expenses		250			1,094			(689	)		754
	$	17,360		$	11,375		$	6,875		$	7,055

TODOS MEDICAL LTD.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Cont.)

(U.S. dollars in thousands)